Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Andrew Moreno
Articles by Andrew Moreno
Mouse Model Finds Iron Restriction, Not Excess, Brings Therapeutic Benefit in MDS
Andrew Moreno
Myelodysplastic Syndromes
|
November 21, 2024
The favorable effects from vamifeport pharmacologic iron restriction were enhanced by combination with luspatercept.
Read More
New Human Bone Marrow Organoid Model Helps Optimize MDS Therapy Research
Andrew Moreno
Myelodysplastic Syndromes
|
November 21, 2024
The model's superior engrafting of HSPCs from patients with MDS brings better replication of the disease microenvironment.
Read More
ESAs-Only MDS Management: Does the Real-World Experience Differ from Clinical Trials?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
View More
Can EMR Alerts Help Optimize Luspatercept Dosing in MDS?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
View More
Does Luspatercept Reduce Health Care Systems’ Resource Utilization Burden in MDS?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
View More
Study Investigates Types, Frequency of AEs Before TKI CML Therapy Adjustments
Andrew Moreno
Chronic Myeloid Leukemia
|
November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Read More
Venetoclax Plus Ibrutinib Offers 'Generally Favorable' Safety Profile in CLL
Andrew Moreno
Chronic Lymphocytic Leukemia
|
November 13, 2024
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
Read More
New Data Help Predict Extended Survival After IDH Inhibitors for IDH1-, IDH2-Mutated AML
Andrew Moreno
Acute Myeloid Leukemia
|
November 13, 2024
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Read More
Study Evaluates Mini-Hyper-CVD Plus Inotuzumab, Dose-Dense Blinatumomab for ALL
Andrew Moreno
Acute Lymphoblastic Leukemia
|
November 13, 2024
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Read More
Analysis Uncovers Brentuximab Vedotin Susceptibility Markers for CD30-Positive PTCL
Andrew Moreno
T-Cell Lymphoma
|
November 11, 2024
The study used CRISPR screening to identify susceptibility markers for brentuximab vedotin in CD30-positive PTCLs.
Read More
ASTCT, USCLC Guidance: Allogeneic HSCT for Mycosis Fungoides, Sézary Syndrome
Andrew Moreno
T-Cell Lymphoma
|
November 12, 2024
Consensus clinical practice recommendations regarding use of this potentially curative procedure had previously been absent.
Read More
A Knowledge Review of PTCL Subtypes’ Pathobiology Aids Management
Andrew Moreno
T-Cell Lymphoma
|
November 8, 2024
Recent advances in knowledge about PTCL biology help inform clinical trial design and use of precision therapy.
Read More
KOMET-001 Phase I Trial: Oral Selective Menin Inhibitor AML Treatment Shows Promise
Andrew Moreno
Acute Myeloid Leukemia
|
November 6, 2024
The phase II component of this clinical trial evaluating ziftomenib for heavily pretreated AML is in progress.
Read More
Outcomes Vary by Patient Age, Frailty Following Multiple Myeloma CAR-T
Andrew Moreno
Print
|
November 5, 2024
A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy.
Read More
Durcabtagene Autoleucel Demonstrates High Responses, Manageable Safety in MM
Andrew Moreno
Print
|
November 4, 2024
A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy.
Read More
Secondary T-Cell Lymphomas Following CAR-T: How Involved Are Vector Insertions in Oncogenesis?
Andrew Moreno
T-Cell Lymphoma
|
November 13, 2024
Co-authors of a new review article suggest other factors more strongly influence secondary tumor development.
Read More
Risk, Genetics of Secondary Tumors Following CAR T-Cell Therapy Investigated
Andrew Moreno
T-Cell Lymphoma
|
November 13, 2024
A single-center study compared the secondary and initial tumors and assessed vector viral integration's role in oncogenesis.
Read More
Selinexor Approved for Third Malignancy Indication in South Korea
Andrew Moreno
Print
|
November 4, 2024
The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults.
Read More
CAR T-Cell Therapy Found Effective, Safe for MCL With Secondary CNS Disease
Andrew Moreno
Transplantation & Cellular Therapy
|
October 24, 2024
A study has compared responses with anti-CD19 CAR-T therapy in MCL with and without active CNS involvement at infusion.
Read More
Axi-Cel, Mosunetuzumab Compared for Third-Line Follicular Lymphoma Management
Andrew Moreno
Transplantation & Cellular Therapy
|
October 24, 2024
An MAIC analysis of data from clinical trials identified differences in efficacy and safety between the two interventions.
Read More
Load More